Falk Symposium 187

Overcoming Challenges in IBD Management

April 19 – 20, 2013
Palau de Congressos de Catalunya
Barcelona, Spain

General Information:
FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany
Congress Division
Telephone: +49 (0)761/1514-0
Telefax: +49 (0)761/1514-359
E-Mail: symposia@falkfoundation.de
www.falkfoundation.org

Program

11 CME credits Awarded
11 credit hours (CME) have been awarded for the Falk Symposium 187 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

Dear colleagues,

Inflammatory bowel diseases impose significant challenges to patients’ life from the time of diagnosis, and in a number of patients a complicated course of the diseases results in successive challenges to their personal, familial, social, and professional development.

Inflammatory bowel diseases become also a challenge for the treating health care professionals, physicians, surgeons and nurses included. These challenges are not only related to the management of complicated disease, but to the development of a treatment plan for every patient, tailored to the patient’s needs and expectations, by making an optimal use of available medical and surgical options, and adopting measures to prevent disease- and treatment- related complications.

The objective of the 187 Falk Symposium that takes place in Barcelona in April 2013 is to gather the best science and clinical experience to guide medical care. The faculty members participating in the program are all among the world leaders in research and education in IBD, and the topics covered include basic concepts helping to understand the mechanisms of inflammatory bowel disease, the integration of novel diagnostic techniques in clinical practice, the optimal use of the current therapeutic armamentarium, and what we should be ready to incorporate in the foreseeable future. Furthermore, there is also the opportunity that attendees share their own research work at the poster sessions. Overall, the program will provide the basis for Overcoming Challenges in IBD Management.

Barcelona, the capital of Catalonia, has an intense life, and the venue will also provide the opportunity to enjoy this attractive city, as well as some of the interesting surroundings not commonly visited during scientific events.

Julián Panés
Chairman of the Scientific Committee
Overcoming Challenges in IBD Management

Palau de Congressos de Catalunya
Barcelona, Spain

Registration:
Thursday, April 18, 2013
16.00 – 21.00 h
at the congress office

Scientific Organization:
J. Panés, Barcelona (Spain)
S. Ghosh, Calgary (Canada)
F. Gomollón, Zaragoza (Spain)
E. Louis, Liège (Belgium)

Congress Venue:
Palau de Congressos de Catalunya
Av. Diagonal 661 - 671
08028 Barcelona
Spain

Information:
Prof. Dr. Julián Panés
Hospital Clínico i Provincial
Universidad de Barcelona
Inflammatory Bowel Disease Unit
c/ Villarroel, 170
08036 Barcelona
Spain
Telephone: +34(0)932/275418
Telefax: +34(0)932/279387
E-Mail: jpanes@clinic.ub.es

Official Language:
English. Simultaneous translation into Spanish.

Posters:
For details see page 10.
Friday, April 19, 2013

8.50 Welcome
J. Panés, Barcelona

Session I
Understanding the mechanisms of disease
Chair: M. Allez, Paris; S. Danese, Rozzano

9.00 Exploiting eQTL information to identify causative genes in risk loci for inflammatory bowel disease
M. Georges, Liège

9.30 The role of memory cells in inflammation perpetuation
M. Allez, Paris

10.00 Mechanisms of tissue remodeling in IBD
C. Fiocchi, Cleveland

10.30 Challenging question: Is it possible to stratify IBD on a molecular and microbiologic basis?
S. Schreiber, Kiel

11.00 Coffee break with poster session

Session II
Advanced techniques for diagnosis of IBD
Chair: M. Georges, Liège; S. Ghosh, Calgary

11.30 High-resolution endoscopy, chromoendoscopy and confocal endomicroscopy
R. Kiesslich, Mainz

12.00 Endoscopic assessment of the small bowel
A. R. Eliakim, Tel Hashomer

12.30 Cross-sectional imaging in IBD
S. Danese, Rozzano

13.00 Challenging question: Can we diagnose Crohn’s disease without histology?
A. M. Griffiths, Toronto

13.30 Lunch break with poster session
Friday, April 19, 2013

Session III
Optimal use of available drugs in IBD

Chair: L. Beaugerie, Paris; S. Schreiber, Kiel

14.30 Should we still be using steroids for treating IBD? A. Bitton, Montreal

15.00 Strategic use of immunosuppressants and anti-TNFs in IBD E. Louis, Liège

15.30 Expert use of drugs: Criteria for failure I. Dotan, Tel Aviv

16.00 Challenging question: Is treating IBD an art or a strictly evidence-based matter? B. G. Feagan, London, ON

16.30 Coffee break with poster session

Session IV
Emerging new therapies

Chair: B. G. Feagan, London, ON; E. Louis, Liège

17.00 Cell therapies in IBD E. Ricart, Barcelona

17.30 Anti-adhesion therapy J. Panés, Barcelona

18.00 Modulation of cell signaling S. Ghosh, Calgary

18.30 Challenging question: How do new therapies contribute to personalized medicine in IBD? R. Panaccione, Calgary
Saturday, April 20, 2013

Session V
Best surgical approaches for IBD
Chair: A. Bitton, Montreal; A. Dignass, Frankfurt

9.00  Stricturing disease: Dilation, strictureplasty, and resection  A. D’Hoore, Leuven

9.30  Perforating disease: Conservative and surgical treatment  G. M. Sampietro, Milan

10.00 Best prevention of postoperative recurrence in Crohn’s disease  G. D’Haens, Amsterdam

10.30 Challenging question: Surgery or anti-TNF in steroid-refractory terminal ileal disease?  W. A. Bemelman, Amsterdam

11.00 Coffee break with poster session

Session VI
Managing IBD outside the gut
Chair: S. Ardizzone, Milan; I. Dotan, Tel Aviv

11.30 Dermatologic diseases and treatment-related complications of IBD: Prevention and treatment  S. Ghosh, Calgary

12.00 Ocular manifestations  L. Pablo, Zaragoza

12.30 IBD and liver diseases  H. Tilg, Innsbruck

13.00 Challenging question: Osteoarticular manifestations: Specific treatments and/or treating the intestinal disease?  M. de Vos, Gent

13.30 Presentation of Poster Prizes  J. Panés, Barcelona

13.40 Lunch break with poster session
Saturday, April 20, 2013

Session VII
Cancer in IBD

Chair: Y. Bouhnik, Clichy; J. Panés, Barcelona

14.30 Management of colonic dysplastic lesions
M. Pellisé, Barcelona

15.00 Small bowel dysplasia and cancer in Crohn’s disease
F. Carbonnel, Le Kremlin-Bicêtre

15.30 5-ASA and chemoprevention: Does it work?
L. Peyrin-Biroulet, Vandoeuvre-les-Nancy

16.00 Challenging question: Use of immunosuppressants and biologicals in patients with previous cancer
L. Beaugerie, Paris

Session VIII
Closing lecture

Chair: E. Ricart, Barcelona

16.30 Towards personalized medicine in IBD
S. Vermeire, Leuven
Poster Session

Posters will be exhibited on April 19 – 20, 2013, at the "Palau de Congressos de Catalunya", Barcelona. The authors will be in attendance during coffee and lunch breaks on both days.

1. A systematic review and meta-analysis of pancreatic autoantibody's (PAB) diagnostic accuracy vs standard diagnosis in patients with inflammatory bowel disease

2. CMV infection in IBD: Preliminary results of a prospective study

3. High prevalence of low bone mineral density in new onset of inflammatory bowel disease
   N. Ben Mustapha, M. Cheikh, M. Fekih, M. Serghini, L. Kallel, J. Boubaker, A. Filali (Tunis, TN)

4. Inflammatory bowel disease in Turkish children: An analysis of 127 children

5. Clostridium difficile infection: A permanent challenge in inflammatory bowel disease patients
   R. Cerban, L.S. Gheorghe, R. Vadan, M. Manuc, B. Cotruta, C. Gheorghe (Bucharest, RO)

6. Endoscopic efficacy of two regimes of maintenance therapy in patients with Crohn’s disease aged 7–17 years – Multicenter randomized study

7. Vegetative dysregulation in patients with Crohn’s disease and anemia syndrome
   L.V. Demeshkina, E.V. Zigalo, A.V. Kovaleva (Dnipropetrovsk, Zaporozhye, UA)

8. IL28Ralpha deficiency enforces T cell-dependent experimental colitis via suppression of regulatory T-cells
   H. Dornhoff, S. Doyle, M.F. Neurath, J. Siebler (Erlangen, DE; Seattle, US)

9. Long following of total proctocolectomy with ileo anal anastomosis: A monocentric experience study
   M. Fekih, A. Laabidi, H. Debbabi, L. Kallel, N. Ben Mustapha, M. Serghini, J. Boubaker, A. Filali (Tunis, TN)
10. Alexithymia and Crohn’s disease: A case-control study in 70 patients
   M. Fekih, H. Zalila, H. Ben Ammar, N. Ben Mustapha, M. Serghini, S. Matri,
   J. Boubaker, A. Boussetta, L. Kallel, A. Filali (Tunis, Manouba, TN)

11. Management of perianal fistulas in Crohn’s disease
   M. Fekih, M. Cheikh, N. Ben Mustapha, L. Kallel, M. Serghini, J. Boubaker,
   A. Filali (Tunis, TN)

12. Mucosal healing in ulcerative colitis (UC) after infliximab treatment – Ultrastructural study
   O.C. Fratila, C. Craciun (Oradea, Cluj Napoca, RO)

13. Risks and benefits of the combined therapy in the treatment of severe steroid refractory Crohn’s disease
   A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea (Craiova, RO)

   A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea (Craiova, RO)

15. Central modulatory role of IL-9 in inflammatory bowel disease
   K. Gerlach, H.-A. Lehr, A. McKenzie, M.F. Neurath, B. Weigmann (Erlangen, DE;
   Lausanne, CH; Cambridge, GB)

16. Anti-TNF alpha therapy in patients receiving tuberculosis chemoprophylaxis
   I. Girleanu, A. Trifan, O. Stoica, S. Chiriac, A.-M. Singeap, C. Stanciu (Iasi, RO)

17. Risk factors and incidence for low urinary tract infections in patients with inflammatory bowel disease
   I. Girleanu, A.-M. Singeap, C. Cojocariu, C. Sfarti, A. Trifan (Iasi, RO)

18. Clinical course and treatment options of Crohn’s disease patients in Serbia
   V. Gligorijevic, D. Bojic, M. Krstic, D. Tarabar, A. Nagorni, L. Hadnadjev, P. Dugalic,
   G. Nikolic, B. Maksimovic, T. Brocic, Z. Milenkovic, N. Jojic (Belgrade, Nis, Novi Sad, RS)

19. The utility and cost-effectiveness of testing for latent TB infection in UK inflammatory bowel disease patients initiating anti-TNFα agents
   K. Greveson, S. Capocci, S. Murthy, C. Smith, S. Morris, I. Cropley, M. Hamilton,
   M. Lipman (London, GB)

20. The immunohistochemical assessment of MMP-2, MMP-7 and MMP-9 in IBD
   K. Guzinska-Ustymowicz, K. Niewiarowska, A. Pryczynicz, W. Famulski,
   A. Kemona, D. Cepowicz, M. Gryko (Bialystok, PL)

21. Cytomegalovirus infection reactivation and IBD: What was the primary?
    K. Hospodarska, I. Hospoderskyy (Ternopil, UA)
22. Is occult hepatitis B infection really a serious problem in patients with inflammatory bowel disease
S. Hülagu, O. Sentürk, A. Celebi, G. Sirin, D. Koc, U. Korkmaz, A.E. Duman,
G. Dindar, H. Yılmaz (Kocaeli, TR)

23. Retrospective study of endoscopic polypectomy in ulcerative colitis associated polyps
T. Ilias, O. Fratila, D. Puscasiu (Oradea, RO)

24. Clinical efficacy of two regimens of maintenance therapy in patients with Crohn’s disease aged 7–17 years – Multicenter randomized study
J. Kierkus, B. Iwanczak, M. Dadalski, A. Wegner, U. Grzybowska-Chlebowczyk,
I. Lazowska, J. Maslana, E. Toporowska-Kowalska, G. Czaja-Bulsa, G. Mierzwia,
B. Korczowski, E. Czkwianianc, A. Zabka, E. Szymanska, E. Krzesiek, S. Wiecek,
M. Sladek (Warsaw, Wroclaw, Krakow, Katowice, Kielce, Lodz, Szczecin, Torun,
Rzeszow, Zabrze, PL)

25. Cell therapy on patients with acute attack of ulcerative colitis
O. Knyazev, A.I. Parfenov, P. Scherbakov, A. Konoplaynnikov (Moscow,
Obninsk, RU)

26. Cell therapy and quality of life of patients with inflammatory bowel disease
O. Knyazev, I. Ruchkina, L. Efremov, A.I. Parfenov (Moscow, RU)

27. Mesenchymal stem cells increases the effectiveness of anti-inflammatory therapy with newly diagnosed Crohn’s disease – 4 years of observation
O. Knyazev, A. Konoplaynnikov, I. Ruchkina, A.I. Parfenov, P. Scherbakov (Moscow,
Obninsk, RU)

28. The safety of biological treatment of IBD
M. Konecny, V. Prochazka (Olomouc, CZ)

29. Pseudotumoral colonic form of Crohn’s disease: A series of 16 cases
S. Matri, M. Fekih, B. Ben Slimene, A. Laabidi, N. Ben Mustapha, M. Serghini,
J. Boubaker, L. Kallel, A. Filali (Tunis, TN)

30. Crohn’s disease of the upper gastrointestinal tract: Is this location more severe?
S. Matri, H. Debbabi, A. Laabidi, M. Fekih, N. Ben Mustapha, M. Serghini,
J. Boubaker, L. Kallel, A. Filali (Tunis, TN)

31. Colon polyps distribution analyse in patients with inflammatory bowel disease
V. Mokricka, I. Ozola-Zalite (Riga, LV)

32. Age distribution analyses in adult patients with onset Crohn’s disease
I. Ozola-Zalite, V. Mokricka (Riga, LV)

33. Is anxiety and depression responsible for some symptoms in patients with inflammatory bowel disease (IBD)?
A. Pacurari, C. Banciu, A. Munteanu, C. Serban, I. Romosan (Timisoara, RO)
34. Inflammatory bowel disease – A risk factor for low bone mineral density
   A. Pacurari, A. Munteanu, C. Banciu, C. Serban, I. Romosan (Timisoara, RO)

35. Osteo-articular affecting in IBD – Importance and treatment
   O. Petrascu, V. Birlutiu (Sibiu, RO)

36. Efficacy of infliximab in the treatment of inflammatory bowel disease (IBD) in children
   A. Potapov, M. Venediktova, E. Tsimbalova, A. Anushenko, M. Varichkina
   (Moscow, RU)

37. Switching patients with ulcerative colitis to once daily mesalazine improves outcome and reduces cost in primary and secondary care
   H. Prasher, P. Savania, R. Jazrawi (Leicester, Bucks, GB)

38. The expression of various apoptotic proteins in inflammatory bowel diseases
   A. Pryczynicz, K. Niewiarowska, K. Guzinska-Ustymowicz, W. Famulski, A. Kemona,
   D. Cepowicz, M. Gryko (Bialystok, PL)

39. Long-term outcome of eradication of complex perianal fistula by mucosal advancement flap in IBD patients
   O. Ryska, Z. Serclova, J. Marvan, J. Kalvach (Prague, CZ)

40. The levels of long and short pentraxins in inflammatory bowel disease
    I. Silosi, M. Cojocaru, V. Biciusca, C.A. Silosi, S. Rogoz, I.M. Cojocaru,
    V.M. Boldeanu (Craiova, Bucharest, RO)

41. The role of the Tec-family kinase ltk in the development of inflammatory bowel disease
    S. Steiner, R. Atreya, M.F. Neurath, B. Weigmann (Erlangen, DE)

42. Mannan-binding lectin (MBL) in inflammatory bowel disease
    A. Szala, L. Bak-Romaniszyn, A. Sokolowska, A. Swierzko, L. Durko, E. Malecka-
    Panas, M. Cedzynski (Lodz, PL)

43. Infliximab therapy in children with moderate to severe ulcerative colitis
    M. Szychta, M. Dadalski, P. Landowski, B. Klincewicz, M. Sladek, K. Karolewska-
    Bochenek, G. Czaja-Bulska, E. Jarocka-Cyrta, B. Korczowski, J. Kierkus (Warsaw,
    Gdansk, Poznan, Cracow, Szczecin, Bialystok, Rzeszow, PL)

44. Inducing role of mucosal mast cells during colitis-associated colorectal cancer
    B. Weigmann, M. Stassen, M.F. Neurath (Erlangen, Mainz, DE)

45. The adaptive potential of organism in patients with ulcerative colitis and anemia
    E.V. Zigalo, L.V. Demeshkina, V.M. Zigalo (Dnipropetrovsk, UA)
List of Speakers, Moderators and Scientific Organizers

Dr. Matthieu Allez  
Hôpital Saint-Louis  
Service de Gastroentérologie  
1 Ave. C. Vellefaux  
75010 Paris  
France  
matthieu.allez@sls.aphp.fr

Dr. Sandro Ardizzone  
Ospedale L. Sacco  
Gastrointestinal Unit  
Via G.B. Grassi 74  
20157 Milan  
Italy  
ardizzone.sandro@hsacco.it

Dr. Laurent Beaugerie  
Hôpital Saint Antoine  
Dept. of Gastroenterology  
184, Rue du Faubourg St.-Antoine  
75571 Paris  
France  
laurant.beaugerie@sat.aphp.fr

Prof. Dr. Willem A. Bemelman  
Academic Medical Center  
Meibergdreef 9  
1105 AZ Amsterdam  
The Netherlands  
w.a.bemelman@amc.uva.nl

Dr. Alain Bitton  
McGill University - Health Centre  
Royal Victoria Hospital  
Dept. of Gastroenterology  
687 Pins avenue  
Montreal QC H3A 1A1  
Canada  
alain.bitton@muhc.mcgill.ca

Prof. Dr. Yoram Bouhnik  
Hôpital Beaujon  
Dept. of Gastroenterology  
100, Bd. Général Leclerc  
92118 Clichy  
France  
yoram.bouhnik@gmail.com

Dr. Franck Carbonnel  
Service d’Hépatogastroentérologie  
Centre Hospitalier Universitaire de Bicêtre  
Université Paris Sud  
78 rue du Général Leclerc  
94275 Le Kremlin-Bicêtre  
France  
fcarbonnel7@gmail.com

Dr. Silvio Danese  
Istituto Clinico Humanitas IRCCS  
Dept. of Gastroenterology  
Via Manzoni, 56  
20089 Rozzano  
Italy  
sdanese@hotmail.com

Prof. Dr. Martine de Vos  
Rijksuniversiteit Gent  
Universitair Ziekenhuis  
De Pintelaan 185  
9000 Gent  
Belgium  
martine.devos@ugent.be

Prof. Dr. Geert D’Haens  
Academic Medical Center  
Afdeling MDL C2-112  
Meibergdreef 9  
1105 AZ Amsterdam  
The Netherlands  
g.dhaens@amc.uva.nl

Prof. Dr. André D’Hoore  
University Ziekenhuis  
Gasthuisberg  
Dept. Abdominal Surgery  
Herestraat 49  
3000 Leuven  
Belgium  
andre.dhoore@uz.kuleuven.ac.be
Prof. Dr. Axel Dignass  
Innere Medizin I  
AGAPLESION  
Markus Krankenhaus  
Wilhelm-Epstein-Str. 4  
60431 Frankfurt  
Germany  
axel.dignass@fdk.info

Dr. Iris Dotan  
Tel Aviv Medical Center  
Ichilov Hospital  
Dept. of Gastroenterology  
6, Weizman Street  
64239 Tel Aviv  
Israel  
irisd@tasmc.health.gov.il

Dr. Abraham R. Eliakim  
Sheba Medical Center  
Department of Gastroenterology  
2 Sheba Road  
52621 Tel Hashomer  
Israel  
abraham.eliakim@sheba.health.gov.il

Dr. Brian G. Feagan  
University of Western Ontario  
Robarts Research Institute  
LCTRG  
100 Perth Drive  
London ON N6A 5K8  
Canada  
bfeagan@robarts.ca

Claudio Fiocchi, M.D.  
Professor of Medicine  
The Cleveland Clinic Foundation  
Pathobiology / NC 20  
9500 Euclid Avenue  
Cleveland OH 44195  
USA  
fiocchc@ccf.org

Prof. Dr. Michel Georges  
University de Liège  
GIgA-Research &  
Faculty of Veterinary Medicine  
1 avenue de l’Hôpital  
4000 Liège  
Belgium  
michel.georges@ulg.ac.be

Prof. Dr. Subrata Ghosh  
University of Calgary  
Foothills Hospital  
Dept. of Gastroenterology  
1403 29th St. NW  
Calgary AB T2N 2T9  
Canada  
subrata.ghosh@albertahealthservices.ca

Dr. Fernando Gomollón  
Hospital Clinico Universitario  
Losano Blesa  
Avenida San Juan Bosco 15  
50009 Zaragoza  
Spain  
fgomollon@telefonica.net

Dr. Anne M. Griffiths  
University of Toronto  
The Hospital for Sick Children  
Dept. of Gastroenterology  
Room 1448  
555 University Avenue  
Toronto ON M5G 1X8  
Canada  
anne.griffiths@sickkids.ca

Prof. Dr. Ralf Kiesslich  
Innere Medizin I  
Universitätsmedizin der  
Johannes Gutenberg-Universität  
Langenbeckstr. 1  
55131 Mainz  
Germany  
kiesslich@uni-mainz.de
Dr. Edouard Louis  
C.H.U. Sart Tilman  
Gastroentérologie  
Domain du Sart Tilman  
4000 Liège  
Belgium  
edouard.louis@ulg.ac.be

Dr. Luis Pablo  
Miguel Servet University Hospital  
Dept. of Ophthalmology  
Paseo Isabel La Católica, 1 y 3  
50009 Zaragoza  
Spain  
luispablo@eresmas.com

Prof. Dr. Remo Panaccione  
University of Calgary  
Inflammatory Bowel Disease Clinic, Room 6D30, TRW Building  
3280 Hospital Drive N.W.  
Calgary AB T2N 2T9  
Canada  
rpanacchi@ucalgary.ca

Prof. Dr. Julián Panés  
Hospital Clínico i Provincial  
Universidad de Barcelona  
Inflammatory Bowel Disease Unit  
c/ Villarroel, 170  
08036 Barcelona  
Spain  
jpanes@clinic.ub.es

Dr. Maria Pellisé  
Hospital Clínico i Provincial  
Universidad de Barcelona  
Dept. of Gastroenterology  
c/ Villarroel, 170  
08036 Barcelona  
Spain  
mpellise@clinic.ub.es

Prof. Dr. Laurent Peyrin-Biroulet  
Hôpitaux de Brabois  
C.H.U. de Nancy  
Dept. of Hepato-Gastroenterology  
Allee du Morvan  
54511 Vandoeuvre-les-Nancy  
France  
peyrinbiroulet@gmail.com

Dr. Elena Ricart  
Hospital Clínico i Provincial  
Universidad de Barcelona  
Dept. of Gastroenterology  
c/ Villarroel, 170  
08036 Barcelona  
Spain  
ericart@clinic.ub.es

Dr. Gianluca M. Sampietro  
Ospedale L. Sacco  
Dept. of Surgery  
Gastroenterology and Oncology  
Via G.B. Grassi 74  
20157 Milan  
Italy  
gianluca.sampietro@unimi.it

Prof. Dr. Stefan Schreiber  
Innere Medizin I  
Universitätsklinikum  
Schleswig-Holstein, Campus Kiel  
Arnold-Heller-Str. 3 (Haus 6)  
24105 Kiel  
Germany  
s.schreiber@mucosa.de

Prof. Dr. Herbert Tilg  
Universitätsklinik Innsbruck  
Innere Medizin I  
Anichstr. 35  
6020 Innsbruck  
Austria  
herbert.tilg@i-med.ac.at

Prof. Dr. Severine Vermeire  
University Ziekenhuis  
Gasthuisberg  
Gastro-entérologie  
Herestraat 49  
3000 Leuven  
Belgium  
severine.vermeire@uz.kuleuven.ac.be
**Congress Office**

**During** Falk Symposium 187

Telephone: +49 (0)175/7795327

Palau de Congressos de Catalunya
Av. Diagonal 661-671
08028 Barcelona
Spain

**Opening Hours:**
Thursday, April 18, 2013 16.00 – 21.00 h
Friday, April 19, 2013 7.00 – 19.00 h
Saturday, April 20, 2013 8.30 – 17.00 h

**Congress Fees**

Scientific program of the Falk Symposium 187 € 200,-
Students and residents € 100,-

**Star** OR **Star**

**Day ticket** € 120,-
Students and residents € 60,-

**Employees of pharmaceutical companies and their guests**
Falk Symposium 187 € 600,-

**The congress fees include:**
- Welcome Evening on April 18, 2013
- Refreshments during coffee breaks
- Lunch on April 19 and 20, 2013
- A copy of the abstract volume
**Admission to Scientific Events**

For admission to scientific events your name badge should be clearly visible.

**Congress Report**

The official congress report of the Falk Symposium 187 “Overcoming Challenges in IBD Management” will be published in English in the second half of 2013 by Karger, Switzerland. Orders for this book at a reduced subscription price of € 35,- can be placed at the Congress Office during the congress in Barcelona.

**Airport**

International Airport Barcelona
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue
in the interest of therapeutic progress
Falk Symposia and Workshops
over 250 with almost 130,000 international participants since 1967

Continuing medical education seminars
over 15,500, attended by more than 1.2 million physicians and patients in Germany alone

Comprehensive literature service for healthcare professionals and patients
with more than 200 publications

www.falkfoundation.org www.drfalkpharma.com
Leinenweberstr. 5 79108 Freiburg Germany Tel +49 (0)761/1514-0 Fax +49 (0)761/1514-321 Mail zentrale@drfalkpharma.de
Falk Symposium 187

Overcoming Challenges in IBD Management

April 19 – 20, 2013
Palau de Congressos de Catalunya
Barcelona, Spain

General Information:
FALK FOUNDATION e.V.
Leinenweberstr. 5
79108 Freiburg
Germany
Congress Division
Telephone: +49 (0)761/1514-0
Telefax: +49 (0)761/1514-359
E-Mail: symposia@falkfoundation.de
www.falkfoundation.org

Program